Pyrroles

"Pyrroles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Azoles of one NITROGEN and two double bonds that have aromatic chemical properties.

Descriptor ID	D011758
MeSH Number(s)	D03.383.129.578
Concept/Terms	Pyrroles Pyrroles

Below are MeSH descriptors whose meaning is more general than "Pyrroles".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Azoles [D03.383.129]
Pyrroles [D03.383.129.578]

Below are MeSH descriptors whose meaning is related to "Pyrroles".

Below are MeSH descriptors whose meaning is more specific than "Pyrroles".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Pyrroles" by people in this website by year, and whether "Pyrroles" was a major or minor topic of these publications.

Bar chart showing 135 publications over 27 distinct years, with a maximum of 13 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1998	1	0	1
2000	0	2	2
2001	3	0	3
2002	3	0	3
2003	1	0	1
2004	3	2	5
2005	3	2	5
2006	0	2	2
2007	3	2	5
2008	3	4	7
2009	2	0	2
2010	2	2	4
2011	6	3	9
2012	6	4	10
2013	5	1	6
2014	6	3	9
2015	1	0	1
2016	2	2	4
2017	1	0	1
2018	1	1	2
2019	8	0	8
2020	7	2	9
2021	7	6	13
2022	0	7	7
2023	1	6	7
2024	5	3	8

Below are the most recent publications written about "Pyrroles" by people in Profiles.

Ailani J, Lipton RB, Blumenfeld AM, Mechtler L, Klein BC, He MY, Smith JH, Trugman JM, de Abreu Ferreira R, Brand-Schieber E. Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study. Headache. 2025 06; 65(6):1005-1014.

View in: PubMed
Talasila S, Lee E, Teichner EM, Siegfried EC, Jackson Cullison SR. Analysis of publicly available adverse events reported for pediatric patients treated with Janus kinase inhibitors. Pediatr Dermatol. 2024 Nov-Dec; 41(6):1040-1046.

View in: PubMed
Lipton RB, Harriott AM, Ma JY, Smith JH, Stokes J, Gandhi P, Jariwala-Parikh K, Jensen GS, Trugman JM, Dodick DW. Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME Trial. Neurology. 2024 Sep 24; 103(6):e209745.

View in: PubMed
Lipton RB, Nahas SJ, Pozo-Rosich P, Bilchik T, McAllister P, Finnegan M, Liu Y, Chalermpalanupap N, Dabruzzo B, Dodick DW. Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial. J Headache Pain. 2024 May 21; 25(1):83.

View in: PubMed
Rizzoli P, Marmura MJ, Robblee J, McVige J, Sacco S, Nahas SJ, Ailani J, De Abreu Ferreira R, Ma J, Smith JH, Dabruzzo B, Ashina M. Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials. J Headache Pain. 2024 Mar 11; 25(1):35.

View in: PubMed
Porreca F, Navratilova E, Hirman J, van den Brink AM, Lipton RB, Dodick DW. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia. 2024 03; 44(3):3331024241238153.

View in: PubMed
Tassorelli C, Onishchenko K, Halker Singh RB, Duan M, Dupont-Benjamin L, Hemstock M, Voller C, McAllister P, Nahas SJ, Gandhi P, Ailani J. Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis. Cephalalgia. 2024 02; 44(2):3331024241235156.

View in: PubMed
Katz MG, Hadas Y, Shtraizent N, Ravvin S, Madjarov JM, Eliyahu E. Unilateral Lung Removal in Combination with Monocrotaline or SU5416 in Rodents: A Reliable Model to Mimic the Pathology of the Human Pulmonary Hypertension. Methods Mol Biol. 2024; 2803:173-185.

View in: PubMed
Dodick DW, Goadsby PJ, Schwedt TJ, Lipton RB, Liu C, Lu K, Yu SY, Severt L, Finnegan M, Trugman JM. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet. 2023 12 16; 402(10419):2307-2316.

View in: PubMed
Li D, Abreu J, Tepper SJ. A Brief Review of Gepants. Curr Pain Headache Rep. 2023 Sep; 27(9):479-488.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement